文献速递结核与非结核分枝杆菌

高剂量利福平、莫西沙星和SQ109治疗结核病的多臂多阶段随机对照试验

High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
PubMed 文献 · Lancet Infect Dis · 2016-10-26

该试验在南非和坦桑尼亚7个中心进行,纳入365例新诊断、利福平敏感、未经治疗的肺结核患者,随机分配至不同方案。

要点

  • 35 mg/kg利福平可缩短液体培养基培养转阴时间,且安全性可接受。
  • 含SQ109的方案因未达到预设疗效阈值而提前终止。
  • 莫西沙星方案未显示培养转阴时间优势。

核心结论

  • 35 mg/kg利福平安全,可缩短液体培养基培养转阴时间,有望成为未来更短方案的组成部分。

研究设计与样本

  • 随机对照、开放标签、多臂多阶段设计,在南非和坦桑尼亚7个中心进行。
  • 纳入365例新诊断、利福平敏感、未经治疗的肺结核患者,按1:1:1:1:2随机分配。

主要发现

  • 其他实验组液体培养基培养转阴时间与对照组无显著差异。
  • 固体培养基培养转阴时间各组无差异。
  • 45例(12%)报告3-5级不良事件,各组比例相似。

关键数值与推荐

  • 主要终点为12周内液体培养基培养转阴时间。
  • SQ109组因预设疗效阈值未达到而提前终止招募。

临床怎么用

  • 高剂量利福平(35 mg/kg)可作为未来短程方案的候选组分。
  • 需进一步研究确认其在不同人群中的疗效与安全性。

局限性

  • 开放标签设计,因利福平高剂量导致体液橙染而无法对患者和临床医生设盲。
  • SQ109组提前终止,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tuberculosis is the world's leading infectious disease killer. We aimed to identify shorter, safer drug regimens for the treatment of tuberculosis. METHODS: We did a randomised controlled, open-label trial with a multi-arm, multi-stage design. The trial was done in seven sites in South Africa and Tanzania, including hospitals, health centres, and clinical trial centres. Patients with newly diagnosed, rifampicin-sensitive, previously untreated pulmonary tuberculosis were randomly assigned in a 1:1:1:1:2 ratio to receive (all orally) either 35 mg/kg rifampicin per day with 15-20 mg/kg ethambutol, 20 mg/kg rifampicin per day with 400 mg moxifloxacin, 20 mg/kg rifampicin per day with 300 mg SQ109, 10 mg/kg rifampicin per day with 300 mg SQ109, or a daily standard control regimen (10 mg/kg rifampicin, 5 mg/kg isoniazid, 25 mg/kg pyrazinamide, and 15-20 mg/kg ethambutol). Experimental treatments were given with oral 5 mg/kg isoniazid and 25 mg/kg pyrazinamide per day for 12 weeks, followed by 14 weeks of 5 mg/kg isoniazid and 10 mg/kg rifampicin per day. Because of the orange discoloration of body fluids with higher doses of rifampicin it was not possible to mask patients and clinicians to treatment allocation. The primary endpoint was time to culture conversion in liquid media within 12 weeks. Patients without evidence of rifampicin resistance on phenotypic test who took at least one dose of study treatment and had one positive culture on liquid or solid media before or within the first 2 weeks of treatment were included in the primary analysis (modified intention to treat). Time-to-event data were analysed using a Cox proportional-hazards regression model and adjusted for minimisation variables. The proportional hazard assumption was tested using Schoelfeld residuals, with threshold p<0·05 for non-proportionality. The trial is registered with ClinicalTrials.gov (NCT01785186). FINDINGS: Between May 7, 2013, and March 25, 2014, we enrolled and randomly assigned 365 patients to different treatment arms (63 to rifampicin 35 mg/kg, isoniazid, pyrazinamide, and ethambutol; 59 to rifampicin 10 mg/kg, isoniazid, pyrazinamide, SQ109; 57 to rifampicin 20 mg/kg, isoniazid, pyrazinamide, and SQ109; 63 to rifampicin 10 mg/kg, isoniazid, pyrazinamide, and moxifloxacin; and 123 to the control arm). Recruitment was stopped early in the arms containing SQ109 since prespecified efficacy thresholds were not met at the planned interim analysis. Time to stable culture conversion in liquid media was faster in the 35 mg/kg rifampicin group than in the control group (median 48 days vs 62 days, adjusted hazard ratio 1·78; 95% CI 1·22-2·58, p=0·003), but not in other experimental arms. There was no difference in any of the groups in time to culture conversion on solid media. 11 patients had treatment failure or recurrent disease during post-treatment follow-up: one in the 35 mg/kg rifampicin arm and none in the moxifloxacin arm. 45 (12%) of 365 patients reported grade 3-5 adverse events, with similar proportions in each arm. INTERPRETATION: A dose of 35 mg/kg rifampicin was safe, reduced the time to culture conversion in liquid media, and could be a promising component of future, shorter regimens. Our adaptive trial design was successfully implemented in a multi-centre, high tuberculosis burden setting, and could speed regimen development at reduced cost. FUNDING: The study was funded by the European and Developing Countries Clinical Trials partnership (EDCTP), the German Ministry for Education and Research (BmBF), and the Medical Research Council UK (MRC).

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Boeree MJ, Heinrich N, Aarnoutse R, et al. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis. 2016. PMID: 28100438. doi:10.1016/S1473-3099(16)30274-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。